Dopamine content in the stratum of Parkinson’s disease rats after transplantation of tyrosine hydroxylase-modified human umbilical cord blood mesenchymal stem cells

doi:10.3969/j.issn.2095-4344.2014.45.013

Abstract

Abstract:

BACKGROUND: Stem cell therapy is superior to drug therapy for recovery of patient’s physiological mode, and cell transplantation therapy is becoming a trend.

OBJECTIVE: To observe the changes in dopamine content in the stratum of Parkinson’s disease rats after transplantation of tyrosine hydroxylase-modified human umbilical cord blood mesenchymal stem cells.

METHODS: After identification by enzyme digestion, pEGFP-C2-TH plasmid was transfected into the fourth generation of human umbilical cord blood mesenchymal stem cells by electroporation method, and then transfected cells were injected into the right cerebral ventricle of Parkinson’s disease rats (experimental group). PBS injection was performed in the control group. Migration of dopamine in the brain tissue of rats was observed, and the content of dopamine was detected by high performance liquid chromatography．

RESULTS AND CONCLUSION: At 8 weeks after cell transplantation, the cells gradually migrated to the ventricles; after 12 weeks, the cells migrated to the cortex, and expressed tyrosine hydroxylase antigen. Meanwhile, the content of dopamine was significantly higher in the experimental group than the control group (P < 0.05). These results reveal that the intraventricular transplantation of tyrosine hydroxylase-modified human umbilical cord blood mesenchymal stem cells has obvious therapeutic effect on Parkinson’s disease rats.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: cord blood stem cell transplantation, Parkinson disease, tyrosine 3-monooxygenase, dopamine

CLC Number:

R394.2

Fan Zhi-gang, Qiao Lei. Dopamine content in the stratum of Parkinson’s disease rats after transplantation of tyrosine hydroxylase-modified human umbilical cord blood mesenchymal stem cells[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(45): 7285-7289.

Figures/Tables 6

References

[1]Lewitt PA.Levodopa for the treatment of Parkinson's disease.N Engl J Med. 2008;359(23):2468-2476.
[2]Olanow CW, Kordower JH, Lang AE,et al.Dopaminergic transplantation for Parkinson's disease: current status and future prospects.Ann Neurol. 2009;66(5):591-596.
[3]de Lau LM, Breteler MM.Epidemiology of Parkinson's disease.Lancet Neurol. 2006;5(6):525-535.
[4]Zhang ZX, Roman GC, Hong Z,et al.Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai.Lancet. 2005; 365(9459):595-597.
[5]王刚,陈生弟.老龄化社会的阵痛一老年性神经变性疾病的社会解读[J].医学与哲学,2006,27(1):59-60.
[6]陈生弟,王刚.帕金森病药物治疗的现状与展望[J].中华神经科杂志,2008,41(3):206-209.
[7]Diaz NL, Waters CH.Current strategies in the treatment of Parkinson's disease and a personalized approach to management.Expert Rev Neurother. 2009;9(12):1781-1789.
[8]高国栋,张华,王学廉,等.帕金森病的定向手术适应证[J].中华神经外科杂志,2002,18(1):12-14.
[9]付文玉,郑志娟,吕娥,等. 移植间充质干细胞治疗帕金森病大鼠[J].基础医学与临床,2010,30(1):42-47.
[10]刘晓艳,康慧聪,胡琦,等.基因修饰的骨髓间充质干细胞移植治疗帕金森病的实验研究[J].华中科技大学学报:医学版,2011,40(4): 396-399.
[11]赵钢勇,张平,赵慧新,等.移植脑源性神经生长因子修饰骨髓间充质干细胞对帕金森病大鼠模型治疗作用的实验研究[J].重庆医科大学学报,2013,38(1):28-32.
[12]孟涛,林玲,郑志,等.大鼠胚胎中脑腹侧细胞和大脑皮质神经干细胞移植治疗帕金森病大鼠的比较[J]. 神经解剖学杂志,2009, 25(5):493-496.
[13]宋承伟,方明,高开波,等.自体外周血造血干细胞移植治疗帕金森病10例[J].中国组织工程研究与临床康复,2009,13(36): 7186- 7188.
[14]王彤宇,刘建杰. 帕金森病的治疗进展[J].医学综述,2009,15(15): 2327-2331.
[15]杜望春,王坚,丁正同,等.微囊化牛视网膜色素上皮细胞移治疗帕金森大鼠的研究[J].中国病理生理杂志,2007,23(2):361-365.
[16]Yasuhara T, Matsukawa N, Hara K,et al.Transplantation of human neural stem cells exerts neuroprotection in a rat model of Parkinson's disease.J Neurosci. 2006;26(48):12497-12511.
[17]赵俊暕,陈乃耀,石峻,等.人脐血间充质干细胞移植对创伤性脑损伤大鼠VEGF分泌及血管新生的影响[J].中国神经免疫学和神经病学杂志,2013,20(4):267-273.
[18]包新民,舒斯云.大鼠脑立体定位图谱[M].北京:人民卫生出版社, 1991:44.
[19]丁妍,卢智勇,袁雅红,等.脐血浆分离培养人脐带间充质干细胞[J].解剖学杂志,2013,36(2):144-147.
[20]杨新玲,马青平,贾丛康,等.胰岛素联合骨髓基质干细胞治疗帕金森病模型鼠[J].中华实验外科杂志,2010,27(1):87-89.
[21]Liu ZH, Jing YH, Yin J, et al. Downregulation of thioredoxin reductase 1 expression in the substantia nigra pars compacta of Parkinson’s disease mice. Neural Regen Rese. 2013; 8(35): 3275-3283.
[22]徐胜利,周明,陈彪.神经营养因子基因修饰的神经干细胞在帕金森病大鼠模型中的治疗作用[J].中华老年医学杂志,2010,29(1): 58-62.
[23]张可华,蔡哲.神经干细胞向多巴胺能神经元分化机制的研究进展[J].中国康复理论与实践,2010,16(4):314-317.
[24]陈强,王秋静,杨东旭,等.骨髓间充质干细胞对大鼠胰腺损伤的修复[J].中国组织工程研究与临床康复,2010,14(23):4252-4256.
[25]Bjugstad KB, Teng YD, Redmond DE Jr,et al.Human neural stem cells migrate along the nigrostriatal pathway in a primate model of Parkinson's disease.Exp Neurol. 2008;211(2): 362-369.
[26]王蒙,杨媛,史春梦,等.人脐血源性MSCs成骨诱导分化前后对DCs的免疫抑制研究[J].免疫学杂志,2012,28(11):959-963.
[27]孙艳,段芳龄,陈香宇,等.体外诱导人脐血间充质干细胞向肝细胞样细胞分化的研究[J].胃肠病学和肝病学杂志,2004,13(3): 239-243.
[28]李恒,李晓红,毕建芬,等.全反式维甲酸促人脐血多能干细胞向多巴胺能神经元分化[J].山东大学学报:医学版,2012,50(6):92-96.
[29]Yao LQ, He C, Zhao Y, et al.Human umbilical cord blood stem cell transplantation for the treatment of chronic spinal cord injury. Neural Regen Rese. 2013; 8(5): 397-403.
[30]郑志娟,庄文欣,付文玉.人脐带间充质干细胞的研究进展[J].解剖科学进展,2008,14(1):100-104.
[31]田晓宁.脐血干细胞的特性及其临床应用[J].中国组织工程研究与临床康复,2009,13(36):7197-7200.
[32]邹志浩,张世忠,姜晓丹,等. 基因修饰骨髓源性神经元样干细胞治疗帕金森大鼠的研究[J].中华神经外科杂志,2010,26(2): 179-182.
[33]刘芳,樊志刚,韩雪飞. 脐血间充质干细胞移植后帕金森病大鼠纹状体内多巴胺含量的变化[J].中国组织工程研究与临床康复, 2010,14(23):4239-4242.